The global angioplasty balloon market is expected to reach a value of
USD 2.9 billion by 2024.

The growth of the market is attributed to favorable government policies,
approval & commercialization of several angioplasty balloons, and
increasing coronary & peripheral interventions. Angioplasty is a
minimally invasive procedure, hence patients and surgeons prefer this
procedure over high cost stent placements.

Furthermore, advancements in the angioplasty balloons are likely to
propel the market. For instance, in December 2014 Medtronic plc received
a U.S. FDA approval for their drug coated balloon IN. PACT Admiral for
the treatment of peripheral artery disease. Approval and
commercialization of cutting and scoring balloons, such as Flextome,
AngioSculpt, TREK and MINI TREK balloon, rising adoption of new
balloons, and lower cost as compared to stent placement are likely to
drive the market during the forecast period.

Further Key Findings From the Study Suggest:

Normal balloon segment dominated the market in 2015 due to low cost
and favorable U.S. FDA policies. Its ability to treat coronary artery
obstruction is further expected to propel the market growth.

Drug-eluting balloon segment is anticipated to be the most lucrative
during the forecast period. This is attributed to increasing
investment in R & D by major players and lower restenosis rates.

Coronary balloon dominated in 2015 and is expected to maintain its
dominance during forecast period. This is due to rising incidence rate
of coronary artery diseases around the globe.

Peripheral is the most lucrative segment owing to launching of new
peripheral products in recent years. Market players are in a process
of introducing newer products with increased efficiency.

Ambulatory surgery centers dominated the end use segment in 2015. They
accounted for the highest share of the vertical as they help minimize
the medical expenses and hospital stay.

Regionally, North America dominated the market in 2015 and is expected
to maintain its position during the forecast period due to local
presence of major market players and high cost of devices as compared
to other regions.

Asia Pacific is anticipated to be fastest growing segment during the
forecast period due to rising healthcare expenditure, growing
investment of key market players in the region, and high patient
population.